Carboplatin in ovarian cancers

Platinum is the standard drug in the treatment of patients with ovarian can cer. The sample of more than 2,000 patients enrolled in randomised trials a nd 2 metaanalyses were largely sufficient to prove that carboplatin and cis platin are equally effective. Carboplatin dose adaptation according to rena l function and AUC decreases drug induced thrombopenia and has allowed carb oplatin to be used widely and safely. Combining carboplatin with paclitaxel has brought additional protection against thrombopenia. The carboplatin-pa clitaxel regimen can be safely administered every 3 weeks in an outpatient setting assuring a better quality of life than the combination of cisplatin and paclitaxel with equal efficacy. Carboplatin-paclitaxel has thus recent ly become the standard chemotherapy regimen for patients with advanced ovar ian cancer Forthcoming results of ongoing trials will determine if high car boplatin noses with peripheral hematopoeitic stem cell support in consolida tion;after first line treatment can benefit patients with advanced disease.